Bateman’s laboratory focuses on the causes, diagnosis and future treatments of Alzheimer’s disease (AD). We directly measure the pathology and pathophysiology of AD in humans using multiple techniques. Our group uses a wide variety of assays and techniques from the most basic applications, such as quantitative measurement of stable-isotope labeled peptides, to clinical translational studies in diagnostic and therapeutic biomarkers for AD.

Learn more about us

We’re growing!

The Bateman lab is currently looking for additional team members and has several exciting opportunities for qualified motivated candidates!

Join us
2023 Bateman Headshot - Sid Hastings Photographer

Randall J. Bateman, MD

Principal Investigator

Randall J. Bateman, MD, is the Charles F. and Joanne Knight Distinguished Professor of Neurology at Washington University School of Medicine, director of the Dominantly Inherited Alzheimer Network (DIAN) and director of the DIAN Trials Unit (DIAN-TU).

Bateman’s laboratory investigates the causes and methods of diagnosis and treatment of Alzheimer’s disease (AD) utilizing a wide variety of assays and techniques from…

Read more
Office of Neuroscience Research news release

International Alzheimer’s prevention trial in young adults begins (Links to an external site)

February 7, 2025
International Alzheimer’s prevention trial in young adults begins
The first participants in an international clinical trial aimed at preventing Alzheimer’s disease in young adults at high risk of the disease have been enrolled. The trial, led by Washington University School of Medicine in St. Louis, aims to determine whether stopping the early molecular changes that lead to symptomatic Alzheimer’s disease can prevent the […]

Donate to the Bateman Alzheimer’s research fund.

Donate now